The phrase "a subsequent trial with" is correct and usable in written English.
It can be used when referring to a follow-up or additional trial involving a particular subject or variable.
Example: "The researchers conducted a subsequent trial with a larger sample size to validate their initial findings."
Alternatives: "a follow-up trial involving" or "an additional trial using".
Compared with a subsequent trial with the same bivalent vaccine plus QS-21 at the maximal tolerated dose of 100 μg, the 5000 μg dose of GPI-0100 producomparableantibodyibody titers.
However, further data would be required to validate this observation since a subsequent trial with the tetracycline-treated flies saw fecundity levels return to those previously observed (as for Figure 3; data not shown).
In a subsequent trial with a 33% dose reduction, eight breast cancer patients were treated with 'reasonable' toxicity.
The data from HiFi and a subsequent trial with HFJV [ 4] indicated an increase in adverse cerebral outcomes in infants assigned to the high-frequency arm.
The authors did find, however, that half the patients who failed a breathing trial with PSV or T-tube tolerated a subsequent trial with ATC and were successfully extubated.
Of concern, an increased risk of severe infections was observed in a subsequent trial involving patients with SLE nephritis who were concurrently taking mycophenolate mofetil and corticosteroids (NCT00573157).
Conclusion: Among women with 1 prior cesarean delivery undergoing a subsequent trial of labor, those with a prior vaginal delivery were at substantially lower risk of uterine rupture than women without a previous vaginal delivery.
In contrast, a subsequent trial suggested that patients with lower mortality risk did not benefit [ 10].
13 A subsequent trial of pain treatment with paracetamol (acetaminophen) in 25 residents in nursing homes reported an increase in general activities and social interaction but no direct improvement in agitation.
Preliminary data from a subsequent trial (n = 104), with volumetric reduction of CNS lesions as its primary endpoint, revealed ≥20% volumetric reduction for 17 patients (16.3%) in whom the median time to volume progression was 16 weeks (range 12 to 24 weeks).
The selectivity of this process has been shown to be variable, however, with a subsequent trial recovering less aluminum (4,725 mg/L concentration and 81% yield) with more DOC carried over (17 mg/L), from a feed of 1,900 mg/L Al and 150 600 mg/L DOC, in the same period of dialysis (Prakash et al., 2004).
